Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Other Operating Expenses (2017 - 2024)

Historic Other Operating Expenses for Avalo Therapeutics (AVTX) over the last 7 years, with Q4 2024 value amounting to $87000.0.

  • Avalo Therapeutics' Other Operating Expenses fell 9763.97% to $87000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $87000.0, marking a year-over-year decrease of 9971.82%. This contributed to the annual value of $27.3 million for FY2024, which is 42542.86% up from last year.
  • As of Q4 2024, Avalo Therapeutics' Other Operating Expenses stood at $87000.0, which was down 9763.97% from -$714000.0 recorded in Q3 2024.
  • Avalo Therapeutics' Other Operating Expenses' 5-year high stood at $27.5 million during Q1 2024, with a 5-year trough of -$714000.0 in Q3 2024.
  • Its 4-year average for Other Operating Expenses is $2.5 million, with a median of $655500.0 in 2021.
  • Within the past 5 years, the most significant YoY rise in Avalo Therapeutics' Other Operating Expenses was 488330.31% (2024), while the steepest drop was 38906.88% (2024).
  • Avalo Therapeutics' Other Operating Expenses (Quarter) stood at $691000.0 in 2021, then fell by 10.27% to $620000.0 in 2022, then surged by 494.52% to $3.7 million in 2023, then plummeted by 97.64% to $87000.0 in 2024.
  • Its last three reported values are $87000.0 in Q4 2024, -$714000.0 for Q3 2024, and $446000.0 during Q2 2024.